Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly average pricing. What happened According to a SEC filing dated February 17, 2026, Braidwell reduced its position in Xenon Pharmaceuticals by 1,779,953 shares. The estimated transaction value was $74.76 million, based on the mean unadjusted closing price during the fourth quarter of 2025. At quarter-end, the stake ...